Stereotactic Radiosurgery for Brain Metastases in Patients With Small Cell Lung Cancer

Victoria H. Wang, BS; Badal Juneja, PhD; Howard Warren Goldman, MD, PhD; Alan Turtz, MD; Chris Bilbao, DO; Qianyi Xu, PhD; Dave Mulvihill, MD; Gary Eastwick, MD; Gregory J. Kubicek, MD

Advances in Radiation Oncology (Sep 2023)

Stereotactic Radiosurgery for Brain Metastases in Patients With Small Cell Lung Cancer

Victoria H. Wang, BS,
Badal Juneja, PhD,
Howard Warren Goldman, MD, PhD,
Alan Turtz, MD,
Chris Bilbao, DO,
Qianyi Xu, PhD,
Dave Mulvihill, MD,
Gary Eastwick, MD,
Gregory J. Kubicek, MD

Affiliations

Victoria H. Wang, BS: Cooper Medical School of Rowan University, Camden, New Jersey
Badal Juneja, PhD: Department of Radiation Oncology, MD Andersen Cancer Center at Cooper University Healthcare, Camden, New Jersey
Howard Warren Goldman, MD, PhD: Department of Neurological Surgery, Cooper University Hospital, Camden, New Jersey
Alan Turtz, MD: Department of Neurological Surgery, Cooper University Hospital, Camden, New Jersey
Chris Bilbao, DO: Department of Neurological Surgery, Cooper University Hospital, Camden, New Jersey
Qianyi Xu, PhD: Department of Radiation Oncology, MD Andersen Cancer Center at Cooper University Healthcare, Camden, New Jersey
Dave Mulvihill, MD: Department of Radiation Oncology, MD Andersen Cancer Center at Cooper University Healthcare, Camden, New Jersey
Gary Eastwick, MD: Department of Radiation Oncology, MD Andersen Cancer Center at Cooper University Healthcare, Camden, New Jersey
Gregory J. Kubicek, MD: Department of Radiation Oncology, MD Andersen Cancer Center at Cooper University Healthcare, Camden, New Jersey; Corresponding author: Gregory J. Kubicek, MD.

Journal volume & issue: Vol. 8, no. 5
p. 101237

Abstract

Read online

Purpose: Treatment of small cell lung cancer (SCLC) with brain metastatic disease has traditionally involved whole brain radiation therapy (WBRT). The role of stereotactic radiosurgery (SRS) is unclear. Methods and Materials: Our study was a retrospective review of an SRS database evaluating patients with SCLC who received SRS. A total of 70 patients and 337 treated brain metastases (BM) were analyzed. Forty-five patients had previous WBRT. The median number of treated BM was 4 (range, 1-29). Results: Median survival was 4.9 months (range, 0.70-23.9). The number of treated BM was correlated with survival; patients with fewer BM had improved overall survival (P 5 treated BM. Patients with previous WBRT had worse brain failure rates (P 5 BM have high rates of subsequent brain failure and are not ideal candidates for SRS.

Published in Advances in Radiation Oncology

ISSN: 2452-1094 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.journals.elsevier.com/advances-in-radiation-oncology/

About the journal